Glioblastomas (GBM) are among the most aggressive and therapy-resistant tumors of the central nervous system and present both clinicians and researchers with immense challenges. Despite significant advances in diagnostics and an improvement in standard therapy, which usually consists of surgical resection, subsequent radiotherapy and the administration of temozolomide, the survival prospects are still unsatisfactory. This is mainly due to the pronounced resistance, the complex tumor heterogeneity and the immunomodulating properties of glioblastoma cells and their microenvironment.
You May Also Like
- Evidence, effectiveness and practical implications
Medicinal plants for allergic rhinitis
- Current status and future prospects
Cell and gene therapies in modern cardiology
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people